+91-8668442535
Home / Biotechnology / Circulatin

Circulating Tumor Cells Prognostic Technologies Market By Technology (Tumor Cells Enrichment, Tumor Cells Detection), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Industry Outlook

The circulating tumor cells prognostic technologies market is expected to reach $12,443.3 million by 2026, up from $2,324.7 million in 2017, with a compounded annual growth rate (CAGR) of 20.8% from 2018 to 2026. As per the latest research findings of the World Health Organization (WHO) for 2018, cancer is the second-largest cause of death globally, with an estimation of 9.6 million deaths in 2018. Worldwide, approximately 1 in 6 deaths occur due to cancer, with 70% of the deaths occurring in low- and middle-income countries.

Cancer is a universal term for a group of diseases that affect different parts of the human body; it is also known as a neoplasm or malignant tumor. Cancer is the rapid creation of abnormal cells that grow from their site of origin and invade other organs through a process known as metastasis, which is usually facilitated by circulating tumor cells. Metastasis is the major cause of death in cancer patients.

Market Synopsis

Technological advancement in the cell enrichment segment will drive the circulating tumor cells market.

Cell enrichment technology currently dominates the circulating tumor cell prognostic technology market. Recent technological advancement in cell enrichment techniques such as filtration, centrifugation, and immunomagnetic methods has resulted in improvised CTC functional characterization, which finds prominence in disease diagnosis and target therapy. Another factor that drives the cell enrichment technology market is its increased adoption in biotechnology industries due to its excellent accuracy and reliable methodology. Cell detection technology will foster impressive growth during the forecast period owing to the introduction of innovative and reproducible molecular biology techniques, such as the isolation of CTC clusters from unprocessed blood. Standardization of optical methods in cell detection has resulted in multicenter clinical trial studies.

The rising incidence of breast cancer in women throughout the globe has resulted in positive traction for CTC’s prognostic technologies market.

Breast cancer is the most common type of cancer in women worldwide, with a variegated prevalence rate ranging from 19.3 cases per 100,000 women in East Africa to 89.7 cases per 100,000 women in the Western European region. In developing nations, breast cancer is diagnosed in late stages, which results in a low survival rate. Researchers throughout the globe are developing biomarkers such as CK3-11D5 and HER2 for the effective diagnosis of non-metastatic breast cancer in women. Prostate cancer will exhibit impressive growth during the forecast period on account of factors such as old age and testosterone imbalance in men. The prevalence rate is high in developed regions such as Europe and North America as people consume diets rich in fat, such as dairy products and red meat, which stimulate the excessive production of testosterone, leading to the onset of prostate cancer. Epic Sciences, Inc., has developed the AR-V7 liquid biopsy test for the accurate prognosis of patients suffering from metastatic prostate cancer.

The Asia Pacific market is driven by the increasing number of patients suffering from cancer and increased funding in R&D to develop CTC’s prognostic technologies.

With 45% of the regional market, North America currently holds the largest share. The key parameters responsible for its dominance are the rising prevalence of cancer and increasing public health awareness, resulting in early diagnosis. A few key players, such as AVIVA Biosciences and Epic Sciences, Inc., have catered to the prognostic needs of prostate and breast cancer in North America. According to World Health Organization (WHO) 2015 statistics, cancer is responsible for 20% of deaths in Europe. The European market for CTC prognostic technologies is being driven by developed healthcare infrastructure and effective cancer treatment guidelines. Asia Pacific serves as a lucrative market on account of factors such as the increasing number of patients suffering from cancer and excellent research activities pertaining to the development of biomarkers and antigens for cancer detection.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

To determine market estimation and compounded annual growth rate (CAGR), qualitative and quantitative market analyses were performed. The market is divided into three parts: technology, application, and geography.

Market estimation and compounded annual growth rate (CAGR) for the report on circulating tumor cells prognostic technologies were determined by applying organic and inorganic market analysis. The technological innovations pertaining to the different types of CTCs being applied for the prognosis of cancer are thoroughly discussed in the scope of the report. The key players spearheading the circulating tumor cells prognostic technologies market are Celula, Inc., Advanced Cell Diagnostics, Inc., Epic Sciences, Inc., AdnaGen GmbH, Fluxion Biosciences, Inc., AVIVA Biosciences Corporation, Rarecells USA, Inc., Vitatex, Inc., Silicon Biosystems S.p.A., and Veridex, LLC.

Key questions are answered in this report.

  • What are the market estimation and compound annual growth rate (CAGR) for CTC’s prognostic technologies market?
  • Who are the key players actively engaged in developing CTC’s prognostic technologies?
  • What are the latest market trends and the level of competition existing among key players in the CTC’s prognostic technologies market?
  • Which is the leading and fastest-growing technology segment in the CTC’s prognostic technologies market?
  • Which is the leading and fastest-growing application segment in the CTC’s prognostic technologies market?
  • Which is the leading and fastest-growing regional segment in the CTC’s prognostic technologies market?

Frequently Asked Questions:

The market for Circulating Tumor Cells Prognostic Technologies Market is expected to reach US$ 12,443.3 Mn by 2026.

The Circulating Tumor Cells Prognostic Technologies Market is expected to see significant CAGR growth over the coming years, at 20.8%.

The report is forecasted from 2018-2026.

The base year of this report is 2016.

Celula, Inc., Advanced Cell Diagnostics, Inc., Epic Sciences, Inc., AdnaGen GmbH, Fluxion Biosciences, Inc., AVIVA Biosciences Corporation, Rarecells USA, Inc., Vitatex, Inc., Silicon Biosystems S.p.A., and Veridex, LLC. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2018
Category:  Biotechnology
Report ID:   59383
Report Format:   PDF
Pages:   120
Rating:    4.4 (66)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support